The Antihormonal Cancer Therapies market was valued at US$ xx in 2023. The market for Antihormonal Cancer Therapies is projected to grow from US$ xx million in 2024, and is projected to reach xx by 2031, at a CAGR of xx% during the forecast period. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values are estimated based on manufacturers' revenue.
The report offers detailed coverage of Antihormonal Cancer Therapies industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Antihormonal Cancer Therapies by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
In addition to this data, the report provides insight into drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Antihormonal Cancer Therapies market are discussed.
The market is segmented by types:
Radiations
Drugs
Surgeries
Others
It can be also divided by applications:
Breast Cancer
Prostate Cancer
Other
And this report covers the historical situation, present status and the future prospects of the global Antihormonal Cancer Therapies market for 2021-2031. In this report, we analyze global market from 5 geographies: Asia-Pacific, Europe, North America, Middle East & Africa, South America.
Finally, the report provides detailed profile and data information analysis of leading company.
AstraZeneca
Novartis
Pfizer
Sanofi
Takeda
Roche
Amgen
Samyang Biopharmaceuticals
Tolmar
Bluebird Bio
Bristol-Myers Squibb
Exelixis
Guardant Health
Illumina
Report Includes:
- xx data tables and xx additional tables
- An overview of global Antihormonal Cancer Therapies market
- An detailed key players analysis across regions
- Analyses of global market trends, with historical data, estimates for 2024 and projections of compound annual growth rates (CAGRs) through 2031
- Insights into regulatory and environmental developments
- Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Antihormonal Cancer Therapies market
- Profiles of major players in the industry, including AstraZeneca, Novartis, Pfizer, Sanofi, Takeda.....
Research objectives
To study and analyze the global Antihormonal Cancer Therapies consumption (value & volume) by key regions/countries, product type and application, history data from 2019 to 2021, and Forecast to 2031.
To understand the structure of Antihormonal Cancer Therapies market by identifying its various subsegments.
Focuses on the key global Antihormonal Cancer Therapies manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
To analyze the Antihormonal Cancer Therapies with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Antihormonal Cancer Therapies submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
Global Antihormonal Cancer Therapies Market Report 2024, Forecast to 2031
1 Scope of the Study
1.1 Antihormonal Cancer Therapies Introduction
1.2 Research Programs
1.3 Analysis of Macroeconomic Indicators
1.4 Years Considered
1.5 Methodology
1.6 Data Source
1.7 Research Objectives
2 Antihormonal Cancer Therapies Industry Overview
2.1 Global Antihormonal Cancer Therapies Market Size (Million USD) Comparison by Regions (2024-2031)
2.1.1 Antihormonal Cancer Therapies Global Main Region Market Analysis
2.2 Market Analysis by Type
2.2.1 Radiations
2.2.2 Drugs
2.2.3 Surgeries
2.2.4 Others
2.3 Market Analysis by Application
2.3.1 Breast Cancer
2.3.2 Prostate Cancer
2.3.3 Other
2.4 Global Antihormonal Cancer Therapies Revenue, Sales and Market Share by Manufacturer
2.4.1 Global Antihormonal Cancer Therapies Sales and Market Share by Manufacturer (2019-2023)
2.4.2 Global Antihormonal Cancer Therapies Revenue and Market Share by Manufacturer (2019-2023)
2.4.3 Global Antihormonal Cancer Therapies Industry Concentration Ratio (CR5 and HHI)
2.4.4 Top 5 Antihormonal Cancer Therapies Manufacturer Market Share
2.4.5 Top 10 Antihormonal Cancer Therapies Manufacturer Market Share
2.4.6 Date of Key Manufacturers Enter into Antihormonal Cancer Therapies Market
2.4.7 Key Manufacturers Antihormonal Cancer Therapies Product Offered
2.4.8 Mergers & Acquisitions Planning
2.5 Antihormonal Cancer Therapies Historical Development Overview
2.6 Market Dynamics
2.6.1 Market Opportunities
2.6.2 Market Risk
2.6.3 Market Driving Force
2.6.4 Porter's Five Forces Analysis
2.7 Coronavirus Disease 2019 (Covid-19): Antihormonal Cancer Therapies Industry Impact
2.7.1 How the Covid-19 is Affecting the Antihormonal Cancer Therapies Industry
2.7.2 Antihormonal Cancer Therapies Business Impact Assessment - Covid-19
2.7.3 Market Trends and Antihormonal Cancer Therapies Potential Opportunities in the COVID-19 Landscape
2.7.4 Measures / Proposal against Covid-19
3 Related Market Analysis
3.1 Related Market Overview
3.2 Macro Analysis of Upstream Markets
3.3 Key Players in Related Markets
3.4 Related Markets Trend Analysis
4 Global Antihormonal Cancer Therapies Market Size Categorized by Regions
4.1 Global Antihormonal Cancer Therapies Revenue and Market Share by Regions
4.1.1 Global Antihormonal Cancer Therapies Sales and Market Share by Regions (2019-2023)
4.1.2 Global Antihormonal Cancer Therapies Revenue and Market Share by Regions (2019-2023)
4.2 Europe Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
4.3 APAC Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
4.4 North America Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
4.5 South America Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
4.6 Middle East & Africa Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5 Europe Antihormonal Cancer Therapies Market Size Categorized by Countries
5.1 Europe Antihormonal Cancer Therapies Revenue and Market Share by Countries
5.1.1 Europe Antihormonal Cancer Therapies Revenue by Countries (2019-2023)
5.1.2 Germany Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5.1.3 UK Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5.1.4 France Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5.1.5 Russia Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5.1.6 Italy Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5.1.7 Spain Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
5.2 Europe Antihormonal Cancer Therapies Revenue (Value) by Manufacturers (2019-2023)
5.3 Europe Antihormonal Cancer Therapies Revenue and Market Share by Type (2019-2023)
5.4 Europe Antihormonal Cancer Therapies Revenue and Market Share by Application (2019-2023)
6 Asia-Pacific Antihormonal Cancer Therapies Market Size Categorized by Countries
6.1 Asia-Pacific Antihormonal Cancer Therapies Revenue and Market Share by Countries
6.1.1 Asia-Pacific Antihormonal Cancer Therapies Revenue by Countries (2019-2023)
6.1.2 China Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
6.1.3 Japan Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
6.1.4 Korea Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
6.1.5 India Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
6.1.6 Southeast Asia Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
6.1.7 Australia Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
6.2 Asia-Pacific Antihormonal Cancer Therapies Revenue (Value) by Players (2019-2023)
6.3 Asia-Pacific Antihormonal Cancer Therapies Revenue and Market Share by Type (2019-2023)
6.4 Asia-Pacific Antihormonal Cancer Therapies Revenue and Market Share by Application (2019-2023)
7 North America Antihormonal Cancer Therapies Market Size Categorized by Countries
7.1 North America Antihormonal Cancer Therapies Revenue and Market Share by Countries
7.1.1 North America Antihormonal Cancer Therapies Revenue by Countries (2019-2023)
7.1.2 United States Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
7.1.3 Canada Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
7.1.4 Mexico Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
7.2 North America Antihormonal Cancer Therapies Revenue (Value) by Players (2019-2023)
7.3 North America Antihormonal Cancer Therapies Revenue and Market Share by Type (2019-2023)
7.4 North America Antihormonal Cancer Therapies Revenue and Market Share by Application (2019-2023)
8 South America Antihormonal Cancer Therapies Market Size Categorized by Countries
8.1 South America Antihormonal Cancer Therapies Revenue and Market Share by Countries
8.1.1 South America Antihormonal Cancer Therapies Revenue by Countries (2019-2023)
8.1.2 Brazil Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
8.2 South America Antihormonal Cancer Therapies Revenue (Value) by Players (2019-2023)
8.3 South America Antihormonal Cancer Therapies Revenue and Market Share by Type (2019-2023)
8.4 South America Antihormonal Cancer Therapies Revenue and Market Share by Application (2019-2023)
9 Middle East and Africa Antihormonal Cancer Therapies Market Size Categorized by Countries
9.1 Middle East and Africa Antihormonal Cancer Therapies Revenue and Market Share by Countries
9.1.1 Middle East and Africa Antihormonal Cancer Therapies Revenue by Countries (2019-2023)
9.1.2 GCC Countries Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
9.1.3 Turkey Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
9.1.4 Egypt Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
9.1.5 South Africa Antihormonal Cancer Therapies Revenue and Growth Rate (2019-2023)
9.2 Middle East and Africa Antihormonal Cancer Therapies Revenue (Value) by Players (2019-2023)
9.3 Middle East and Africa Antihormonal Cancer Therapies Revenue and Market Share by Type (2019-2023)
9.4 Middle East and Africa Antihormonal Cancer Therapies Revenue and Market Share by Application (2019-2023)
10 Global Antihormonal Cancer Therapies Market Segment by Type
10.1 Global Antihormonal Cancer Therapies Revenue and Market Share by Type (2019-2023)
10.2 Global Antihormonal Cancer Therapies Market Forecast by Type (2024-2031)
10.3 Radiations Revenue Growth Rate
10.4 Drugs Revenue Growth Rate
10.5 Surgeries Revenue Growth Rate
10.6 Others Revenue Growth Rate
11 Global Antihormonal Cancer Therapies Market Segment by Application
11.1 Global Antihormonal Cancer Therapies Revenue Market Share by Application (2019-2023)
11.2 Global Antihormonal Cancer Therapies Market Forecast by Application (2024-2031)
11.3 Breast Cancer Revenue Growth Rate (2015-2025)
11.4 Prostate Cancer Revenue Growth Rate (2015-2025)
11.5 Other Revenue Growth Rate (2015-2025)
12 Market Forecast for Antihormonal Cancer Therapies
12.1 Global Antihormonal Cancer Therapies Market Size Forecast (2024-2031)
12.2 Antihormonal Cancer Therapies Market Forecast by Regions (2024-2031)
12.3 Europe Antihormonal Cancer Therapies Revenue Market Forecast (2024-2031)
12.4 APAC Antihormonal Cancer Therapies Revenue Market Forecast (2024-2031)
12.5 North America Antihormonal Cancer Therapies Revenue Market Forecast (2024-2031)
12.6 South America Antihormonal Cancer Therapies Revenue Market Forecast (2024-2031)
12.7 Middle East & Africa Antihormonal Cancer Therapies Revenue Market Forecast (2024-2031)
13 Analysis of Antihormonal Cancer Therapies Industry Key Vendors
13.1 AstraZeneca
13.1.1 Company Details
13.1.2 Product Information
13.1.3 AstraZeneca Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.1.4 Main Business Overview
13.1.5 AstraZeneca News
13.2 Novartis
13.2.1 Company Details
13.2.2 Product Information
13.2.3 Novartis Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.2.4 Main Business Overview
13.2.5 Novartis News
13.3 Pfizer
13.3.1 Company Details
13.3.2 Product Information
13.3.3 Pfizer Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.3.4 Main Business Overview
13.3.5 Pfizer News
13.4 Sanofi
13.4.1 Company Details
13.4.2 Product Information
13.4.3 Sanofi Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.4.4 Main Business Overview
13.4.5 Sanofi News
13.5 Takeda
13.5.1 Company Details
13.5.2 Product Information
13.5.3 Takeda Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.5.4 Main Business Overview
13.5.5 Takeda News
13.6 Roche
13.6.1 Company Details
13.6.2 Product Information
13.6.3 Roche Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.6.4 Main Business Overview
13.6.5 Roche News
13.7 Amgen
13.7.1 Company Details
13.7.2 Product Information
13.7.3 Amgen Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.7.4 Main Business Overview
13.7.5 Amgen News
13.8 Samyang Biopharmaceuticals
13.8.1 Company Details
13.8.2 Product Information
13.8.3 Samyang Biopharmaceuticals Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.8.4 Main Business Overview
13.8.5 Samyang Biopharmaceuticals News
13.9 Tolmar
13.9.1 Company Details
13.9.2 Product Information
13.9.3 Tolmar Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.9.4 Main Business Overview
13.9.5 Tolmar News
13.10 Bluebird Bio
13.10.1 Company Details
13.10.2 Product Information
13.10.3 Bluebird Bio Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.10.4 Main Business Overview
13.10.5 Bluebird Bio News
13.11 Bristol-Myers Squibb
13.11.1 Company Details
13.11.2 Product Information
13.11.3 Bristol-Myers Squibb Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.11.4 Main Business Overview
13.11.5 Bristol-Myers Squibb News
13.12 Exelixis
13.12.1 Company Details
13.12.2 Product Information
13.12.3 Exelixis Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.12.4 Main Business Overview
13.12.5 Exelixis News
13.13 Guardant Health
13.13.1 Company Details
13.13.2 Product Information
13.13.3 Guardant Health Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.13.4 Main Business Overview
13.13.5 Guardant Health News
13.14 Illumina
13.14.1 Company Details
13.14.2 Product Information
13.14.3 Illumina Antihormonal Cancer Therapies Revenue and Gross Margin (2019-2023)
13.14.4 Main Business Overview
13.14.5 Illumina News
14 Research Findings and Conclusion
15 Appendix